Olema Pharmaceuticals inc (NAS:OLMA)
$ 6.15 -0.17 (-2.69%) Market Cap: 466.46 Mil Enterprise Value: 253.39 Mil PE Ratio: 0 PB Ratio: 1.82 GF Score: 38/100

Olema Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript

Feb 23, 2023 / 05:00PM GMT
Release Date Price: $4.33 (-5.04%)
Yigal Nochomovitz
Citi - Analyst

Hi, welcome back, everyone. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. This is the continuation of our Virtual Oncology Summit, the third day, the three-day virtual conference. It's my great pleasure to have with me from Olema Pharmaceuticals, Sean Bohen, MD, PhD, the President and CEO of the company.

Sean, thanks so much for stepping away from your day job for a few minutes, and chatting with us about Olema and the pipeline.

So maybe just to kick it off, for those listening that a little bit less familiar with Olema, maybe just walk through at a high level on what you're focused on, and then maybe if you could comment specifically on how your CERAN/SERD approach differs from some of the other approaches in the ER space that people are perhaps a little bit more familiar with, for example, the CERAN, the SERDs, and the ER degraders. So that would be a great place to kick off the conversation.

Sean Bohen
Olema Pharmaceuticals, Inc. - President & CEO

Great, great. Thank you, Yigal,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot